Bears Want to Knock Down USG

By David Russell of OptionMonster
 
NEW YORK -- USG's (USG) been standing stall, and the bears want to knock it down a peg.
 
OptionMonster's tracking programs detected the purchase of more than 4,500 February 32 puts in the building-products company on Friday, most of which priced for $1.90 and $2. The volume was 13 times higher than the strike's previous open interest, indicating that new positions were initiated.
 
Puts lock in the price where a stock can be sold no matter how far it might fall, creating an inverse relationship to their underlying share price. Investors often use them to hedge long positions, but the fact that Friday's contracts were in the money suggests that this trade is a speculative bearish play.
 
USG shares fell 4.49% to $30.62 on Friday. The stock touched $32.39 on Jan. 17, its highest price since the broader market was on the verge of collapse in September 2008. The company's next earnings report is scheduled for the morning of Feb. 6, about two weeks before Friday's puts expire.
 
Total option volume was triple the daily average in the session, with puts outnumbering calls by almost 8 to 1.
 
Russell has no positions in USG.

This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.

If you liked this article you might like

Hot Housing Data Is Powering These Stocks to New 52-Week Highs

Hot Housing Data Is Powering These Stocks to New 52-Week Highs

Activision Blizzard, Xilinx, Priceline Group: 'Mad Money' Lightning Round

Activision Blizzard, Xilinx, Priceline Group: 'Mad Money' Lightning Round

Buy on Weakness: Cramer's 'Mad Money' Recap (Thursday 10/19/17)

Buy on Weakness: Cramer's 'Mad Money' Recap (Thursday 10/19/17)

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round